Carregant...
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy
Despite early benefits seen in cancer patients treated with anti-VEGF pathway targeted drugs, the clinical benefits obtained in terms of progression-free or overall survival have been more modest than expected. This is, at least in part, due to antiangiogenic drug resistance mechanisms that involve...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2743513/ https://ncbi.nlm.nih.gov/pubmed/19671869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0095 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|